SCHEMBL4761672

SCHEMBL4761672

O=C1CCCCN1I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7114325 0.97
SCHEMBL18507052 0.97 BRD4 (0.39)
SCHEMBL1098210 0.92
SCHEMBL9352370 0.89
SCHEMBL9600797 0.76
SCHEMBL23430212 0.73 BRD4 (0.39)
SCHEMBL1440028 0.71 BRD4 (0.43)
SCHEMBL2363506 0.69 BRD4 (0.48)
SCHEMBL11382367 0.69 BRD4 (0.42)
SCHEMBL1457572 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937669-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP claimed
WO-2007027959-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-08 WO claimed
WO-2024050825-A1 COMPOUNDS AS MLKL INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2024-03-14 WO disclosed
US-10981951-B2 Therapeutics for the treatment of glaucoma MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-04-20 US disclosed
US-20210040148-A1 THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-02-11 US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed
EP-3190111-B1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-05-06 EP disclosed
EP-2853265-B1 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha AERPIO THERAPEUTICS INC (US) 2017-07-26 EP disclosed
EP-3190111-A1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-07-12 EP disclosed
EP-2522664-B1 Piperidine derivatives as NK1 antagonists OPKO HEALTH INC (US) 2017-04-12 EP disclosed
EP-1758883-B1 Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors SCHERING CORP (US) 2011-11-02 EP disclosed
WO-2009039248-A2 METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION STANFORD UNIVERSITY (US) 2009-03-26 WO disclosed
US-4017667-A POLLUTION CONTROL THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1977-04-12 US disclosed
US-4017668-A POLLUTION CONTROL THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1977-04-12 US disclosed
US-4012565-A Photodegradable polyolefin composition containing an N-halo hydantoin THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1977-03-15 US disclosed
US-4009324-A Photodegradable polyolefin composition containing an N-halo lactam THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1977-02-22 US disclosed
US-4009325-A Photodegradable polyolefin composition containing an N-halo urethane THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1977-02-22 US disclosed
US-3968095-A Photodegradable plastics containing an N-halo amide THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1976-07-06 US disclosed
US-3932352-A POLYOLEFINS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1976-01-13 US disclosed